secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001140361-25-010575
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech reports FY2024 net loss $37.6M; initiates Phase 3 Versamune HPV trial
--------------------------------------------------------------------------------

- Net loss for FY 2024 was $37.6M ($1.03 per share), compared to $42.9M ($1.39 per share) in 2023; operating expenses decreased to $36.3M from $43.0M.
- Initiated Phase 3 VERSATILE-003 trial for Versamune HPV in HPV16-positive first-line recurrent/metastatic HNSCC; ~350 patients, primary endpoint overall survival.
- FDA cleared IND for combination of Versamune MUC1 and PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma; Phase 1/2 with NCI.
- Cash balance as of Dec 31, 2024 was $41.7M; subsequent $22M registered direct offering in Feb 2025 with $11M upfront proceeds.
- FDA granted Fast Track designation for Versamune HPV + pembrolizumab combination in recurrent/metastatic HNSCC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125010575/0001140361-25-010575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125010575/ef20046266_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-010575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer